Log In
Print
BCIQ
Print
Print this Print this
 

inotuzumab ozogamicin (CMC-544, PF-5208773)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHumanized mAb against CD22 linked to the calicheamicin cytotoxin
Molecular Target CD22
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today